United Bio-Technology (Hengqin)

Peptide therapeutics

Privately held: no public share price · China

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
GLP-1/GIP/glucagon receptor (triple)Peptide
ObesityType 2 DiabetesChronic Kidney Disease
Phase 1
Insulin receptor (basal)Peptide
Type 2 Diabetes

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (5)
January 2027 (1)
UBT251Phase 2Overweight, Obesity
Est. primary completion 2027-01-14 · NCT07395687 · CT.gov ↗
What to watch
June 2027 (1)
UBT251Phase 2Metabolic Dysfunction-associated Steatohepatitis (MASH)
Est. primary completion 2027-06-04 · NCT07145151 · CT.gov ↗
What to watch
September 2027 (2)
UBT251Phase 3Type 2 Diabetes
Est. primary completion 2027-09-24 · NCT07659574 · CT.gov ↗
What to watch
UBT251Phase 3Obesity & Overweight
Est. primary completion 2027-09-29 · NCT07648225 · CT.gov ↗
What to watch
October 2027 (1)
UBT251Phase 2Diabetes Mellitus, Type 2
Est. primary completion 2027-10-04 · NCT07668388 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
UBT251Phase 3Type 2 Diabetes
Est. primary completion 2028-02-29 · NCT07653477 · CT.gov ↗
What to watch
September 2028 (1)
UBT251Phase 3Obstructive Sleep Apnea, Obesity
Est. primary completion 2028-09 · NCT07767942 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
UBT251Phase 3Obstructive Sleep Apnea, Obesity
Est. primary completion 2029-03 · NCT07806851 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
UBT251Phase 2Obesity &Amp; Overweight, Chronic Kidney Disease
Est. primary completion 2030-07-11 · NCT07134335 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.